| Citation: |
YU Jiao, LEI Yu, JIN Ronghui, CHEN Xin. Clinical Observation on Prevention and Treatment Effect of Thalidomide on Acute Radiation Proctitis[J]. Cancer Research on Prevention and Treatment, 2017, 44(5): 351-355. DOI: 10.3971/j.issn.1000-8578.2017.05.008
|
To explore the prevention and treatment effect of thalidomide on acute radiation proctitis, and the influence on the living quality of patients during radiotherapy.
Ninety cervical cancer patients treated with concurrent chemoradiotherapy after surgery were divided randomly into two groups: 45 cases in the experimental group (thalidomide combined with concurrent chemoradiotherapy) and 45 cases in the control group (only concurrent chemoradiotherapy). The two groups were observed on the occurrence of acute radiation proctitis and the changes of Karnofsky score, sleep status, diet status and weight status.
The levels of acute radiation proctitis in the experimental group were lower than that in the control group with statistical significance (P < 0.05). The improvement rates of Karnofsky score, sleep status, diet status and weight status in the experimental group were all better than that in the control group (P < 0.05).
Thalidomide, which can improve the living quality of patients during radiotherapy and guarantee radiotherapy process going smoothly, is a safe and effective method for the prevention and treatment of acute radiation proctitis.
| [1] |
International Commission on Radiation Units and Measurements. Prescribing, recording, and reporting photon-beam intensity-modulated radiation therapy (IMRT)[J]. J ICRU, 2010, 10(1): NP. doi: 10.1093/jicru/ndq002
|
| [2] |
谷铣之, 殷蔚伯, 余子豪, 等.肿瘤放射治疗学[M].北京:中国协和医科大学出版社, 2008: 1043.
Gu XZ, Yin WB, Yu ZH, et al. Radiation Oncology[M]. Beijing: Peking Union Medical College Press, 2008: 1043.
|
| [3] |
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys, 1995, 31(5): 1341-6. doi: 10.1016/0360-3016(95)00060-C
|
| [4] |
孙燕.内科肿瘤学[M].北京:人民卫生出版社, 2003: 994.
Sun Y. Medical Oncology[M]. Beijing: People' s Medical Publishing House, 2003: 994.
|
| [5] |
Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment[J]. Semin Radiat Oncol, 2003, 13(3): 176-81. doi: 10.1016/S1053-4296(03)00031-6
|
| [6] |
贾西彪, 王红静, 杨凌云, 等.宫颈癌根治术后放疗并发症和生活质量分析[J].广东医学, 2011, 32(14): 1907-9. doi: 10.3969/j.issn.1001-9448.2011.14.048
Jia XB, Wang HJ, Yang LY, et al. Analysis of postoperative radiotherapy complications and quality of life in patients with cervical cancer after radical operation[J]. Guangdong Yi Xue, 2011, 32(14): 1907-9. doi: 10.3969/j.issn.1001-9448.2011.14.048
|
| [7] |
高碧燕, 卢玉波, 俞晶, 等.思密达-金因肽混合液保留灌肠治疗急性放射性直肠炎 (附34例分析)[J].现代肿瘤医学, 2006, 14(3): 334-6. http://www.cnki.com.cn/Article/CJFDTOTAL-SXZL200603036.htm
Gao BY, Lu YB, Yu J, et al. Treatment for acute radioactive rectitis with mixed liquor of smecta and genetime retentionenema[J]. Xian Dai Zhong Liu Yi Xue, 2006, 14(3): 334-6. http://www.cnki.com.cn/Article/CJFDTOTAL-SXZL200603036.htm
|
| [8] |
Przemeck SM, Duekworth CA, Pritchard DM. Radiation-induced gastric epithelial apoptosis occurs in the proliferative zone and is regulated by p53, bak, and bcl-2[J]. Am J Physiol Gastrointest Liver Physiol, 2007, 291(2): 620-7. https://www.researchgate.net/publication/6728367_Radiation-induced_gastric_epithelial_apoptosis_occurs_in_the_proliferative_zone_and_is_regulated_by_p53_bak_bax_and_bcl-2
|
| [9] |
Shi J, Aono S, Lu W, et al. A novel role for defensins in intestinal homestasis: regulation of IL-1beta secretion[J]. J Immunol, 2007, 179(2): 1245-53. doi: 10.4049/jimmunol.179.2.1245
|
| [10] |
Citrin D, Cotrim AP, Hyodo F, et al. Radioprotectors and mitigators of radiation-induced normal tissue injury[J]. Oncologist, 2010, 15(4): 360-71. doi: 10.1634/theoncologist.2009-S104
|
| [11] |
Zidi I, Mestiri S, Bartegi A, et al. TNF-alpha and its inhibitors in cancer[J]. Med Oncol, 2010, 27(2) : 185-98. doi: 10.1007/s12032-009-9190-3
|
| [12] |
夏婷婷, 徐洪雨.沙利度胺对溃疡性结肠炎疗效的实验研究[J].中国实用医药, 2016, 11(14): 285-6. http://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201614211.htm
Xia TT, Xu HY. Experimental research of curative effect by thalidomide for ulcerative colitis[J]. Zhongguo Shi Yong Yi Yao, 2016, 11(14): 285-6. http://www.cnki.com.cn/Article/CJFDTOTAL-ZSSA201614211.htm
|
| [13] |
潘骥群, 鲁光平, 于志坚.沙利度胺抗肿瘤的研究进展[J].中华肿瘤防治杂志, 2012, 19(7): 552-5. http://www.cnki.com.cn/Article/CJFDTOTAL-LYYZ200901049.htm
Pan JQ, Lu GP, Yu ZJ. Thalidomide on anti-tumor research[J]. Zhonghua Zhong Liu Fang Zhi Za Zhi, 2012, 19(7): 552-5. http://www.cnki.com.cn/Article/CJFDTOTAL-LYYZ200901049.htm
|
| [14] |
罗潇, 刘学军.沙利度胺通过下调转化生长因子-β1肿瘤坏死因子-α抑制大鼠肺纤维化[J].中国药物与临床, 2010, 10(12): 1346-9. doi: 10.3969/j.issn.1671-2560.2010.12.008
Luo X, Liu XJ. Thalidomide suppresses bleomycin-induced pulmonary fibrosis by down-regulating expressions of TGF-β1 and TNF-α in rats[J]. Zhongguo Yao Wu Yu Lin Chuang, 2010, 10(12): 1346-9. doi: 10.3969/j.issn.1671-2560.2010.12.008
|
| [15] |
郑亚兵, 马胜林, 周卫民, 等.沙利度胺抗Lewis肺癌小鼠癌性恶病质的实验研究[J].北京医学, 2010, 32(7): 559-61. http://www.cnki.com.cn/Article/CJFDTOTAL-BJYX201007032.htm
Zheng YB, Ma SL, Zhou WM, et al. Experimental study of the effectivenes of thalidomide for the treatment of lewis lung cancer cachexia mice[J]. Beijing Yi Xue, 2010, 32(7): 559-61. http://www.cnki.com.cn/Article/CJFDTOTAL-BJYX201007032.htm
|
| [16] |
Chen YY, Yen HH, Chou KC, et al. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis[J]. World J Gastroenterol, 2012, 18(5): 466-71. doi: 10.3748/wjg.v18.i5.466
|
| [17] |
Shao YY, Lin ZZ, Hsu C, et al. Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma[J]. Oncology, 2012, 82(1): 59-66. doi: 10.1159/000336126
|
| [18] |
Hoang T, Dahlberg SE, Schiller JH, et al. Randomized phase Ⅲ study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage Ⅲ non-small-cell lung cancer: the ECOG 3598 study[J]. J Clin Oncol, 2012, 30(6): 616-22. doi: 10.1200/JCO.2011.36.9116
|
| [19] |
Young RJ, Tin AW, Brown NJ, et al. Analysis of circulating angiogenic biomarkers from patients in two phase Ⅲ trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide[J]. Br J Cancer, 2012, 106(6): 1153-9. doi: 10.1038/bjc.2012.50
|
| [20] |
Lv J, Liu N, Liu KW, et al. A randomised controlled phase Ⅱ trial of the combination of XELOX with thalidomide for the first-line treatment of metastatic colorectal cancer[J]. Cancer Bio Med, 2012, 9(2): 111-4. http://pubmedcentralcanada.ca/pmcc/articles/PMC3643658/
|
| [21] |
张静, 康红刚, 王宝中.沙利度胺联合放化疗对小细胞肺癌患者生存质量及耐受性的影响[J].癌症进展, 2016, 14(6): 551-6. http://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201606017.htm
Zhang J, Kang HG, Wang BZ. The effect of thalidomide combined with chemoradiotherapy on the quality of life and tolerance of SCLC patients[J]. Ai Zheng Jin Zhan, 2016, 14(6): 551-6. http://www.cnki.com.cn/Article/CJFDTOTAL-AZJZ201606017.htm
|
| [22] |
张弛, 邓文英, 李宁, 等.沙利度胺改善恶性肿瘤化疗患者生活质量分析[J].肿瘤代谢与营养电子杂志, 2015, 2(3): 49-52. http://www.cnki.com.cn/Article/CJFDTOTAL-ZLDX201503016.htm
Zhang C, Deng WY, Li N, et al. Analysis of thalidomide in the quality of life of the malignant tumor patients treated with chemotherapy[J]. Zhong Liu Dai Xie Yu Ying Yang Dian Zi Za Zhi, 2015, 2(3): 49-52. http://www.cnki.com.cn/Article/CJFDTOTAL-ZLDX201503016.htm
|
| [23] |
江伟, 张章, 齐志峰, 等.沙利度胺对老年肿瘤化疗患者生活质量影响的临床观察[J].中国癌症防治杂志, 2014, 6(1): 70-3. http://www.cnki.com.cn/Article/CJFDTOTAL-ZAZF201401022.htm
Jiang W, Zhang Z, Qi ZF, et al. Clinical study of thalidomide to improve quality of life of geriatric tumor patients on chemotherapy[J]. Zhongguo Ai Zheng Fang Zhi Za Zhi, 2014, 6(1): 70-3. http://www.cnki.com.cn/Article/CJFDTOTAL-ZAZF201401022.htm
|
| [24] |
梁万霞, 顾康生.沙利度胺联合DOF方案与单纯DOF方案一线治疗晚期胃癌的疗效观察[J].肿瘤防治研究, 2015, 42(3): 277-9. doi: 10.3971/j.issn.1000-8578.2015.03.014
Liang WX, Gu KS. Curative effect of DOF combined with thalidomide regimen and DOF regimen alone as first-line treatment for advanced gastric cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2015, 42(3): 277-9. doi: 10.3971/j.issn.1000-8578.2015.03.014
|
| [25] |
Kizer NT, Thaker PH, Gao F, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy[J]. Cancer, 2011, 17(5): 948-56. https://www.researchgate.net/profile/Premal_Thaker/publication/47416126_The_Effects_of_Body_Mass_Index_on_Complications_and_Survival_Outcomes_in_Patients_With_Cervical_Carcinoma_Undergoing_Curative_Chemoradiation_Therapy/links/5418747e0cf203f155adaea1.pdf?origin=publication_list
|
| [26] |
Wijermans P, SchaMsma M, Termorshuizen F, et al. Phase Ⅲ study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study[J]. J Clin Oncol, 2010, 28(19): 3160-6. doi: 10.1200/JCO.2009.26.1610
|
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: